DE2111467A1 - Method for binding heparin to polyethylene terephthalate - Google Patents
Method for binding heparin to polyethylene terephthalateInfo
- Publication number
- DE2111467A1 DE2111467A1 DE19712111467 DE2111467A DE2111467A1 DE 2111467 A1 DE2111467 A1 DE 2111467A1 DE 19712111467 DE19712111467 DE 19712111467 DE 2111467 A DE2111467 A DE 2111467A DE 2111467 A1 DE2111467 A1 DE 2111467A1
- Authority
- DE
- Germany
- Prior art keywords
- heparin
- polyethylene terephthalate
- dry heat
- binding
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000669 heparin Polymers 0.000 title claims description 23
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 21
- 229960002897 heparin Drugs 0.000 title claims description 21
- -1 polyethylene terephthalate Polymers 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 12
- 229920000139 polyethylene terephthalate Polymers 0.000 title claims description 11
- 239000005020 polyethylene terephthalate Substances 0.000 title claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 5
- DVBJBNKEBPCGSY-UHFFFAOYSA-M cetylpyridinium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 DVBJBNKEBPCGSY-UHFFFAOYSA-M 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910017464 nitrogen compound Inorganic materials 0.000 claims description 3
- 230000001453 nonthrombogenic effect Effects 0.000 claims description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical class OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002830 nitrogen compounds Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FTBVOJZWVWWLFB-UHFFFAOYSA-N 2-(octan-2-ylamino)ethanol Chemical compound CCCCCCC(C)NCCO FTBVOJZWVWWLFB-UHFFFAOYSA-N 0.000 description 1
- HGPNKTHAVDVUNT-UHFFFAOYSA-N 2-dodecylpyridine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCC1=CC=CC=[NH+]1 HGPNKTHAVDVUNT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0017—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a surface active agent
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Textile Engineering (AREA)
- Materials For Medical Uses (AREA)
Description
Verfahren zur Bindung von Heparin an PolyathylenterephthalatMethod for binding heparin to polyethylene terephthalate
Die Erfindung betrifft ein "Verfahren zur Bindung von Heparin an Polyathylenterephthalat, sowie die Anwendung zur Herstellung von nichttrombogenen prosthetischen Gegenständen, wie z. B. künstlichen Blutgefässen und dergleichen.The invention relates to a "method for binding heparin." on polyethylene terephthalate, as well as the application for the production of non-thrombogenic prosthetic articles such as B. artificial blood vessels and the like.
Nach dem USA-Patent 2,465,319 können prosthetische Gegenstände aus künstlichen Fasern, insbesondere polymeren Terephthalatestern, entsprechend R. W. Moncrieff, Man-Made Fibers, 4-, Aufl., S. 361-389, hergestellt werden. Besonders hierfür geeignet ist der unter dem Warenzeichen DACROIT allgemein bekannte, aus Terephthalsäure und Äthylenglykol hergestellte Polyester mit der Strukturformel:According to US Patent 2,465,319, prosthetic articles made of artificial fibers, in particular polymeric terephthalate esters, according to R. W. Moncrieff, Man-Made Fibers, 4, ed., pp. 361-389. Particularly The one under the DACROIT trademark is generally suitable for this well-known polyester made from terephthalic acid and ethylene glycol with the structural formula:
HO-HO-
OCOC
109841/1833109841/1833
Bekannt ist auch die gerinnungshemmende Wirkung von Heparin. Wie Gott u. a. in Science, Bd. 14-2, S. 1297 (1965), zeigten, gerinnt Blut nicht, wenn es in mit Graphit überzogene Rohre gegeben wird, die mit einem kationischen, oberflächenaktiven Mittel und Heparin behandelt und mit Salzwasser gesmilt wurden· The anticoagulant effect of heparin is also known. Like God et al. in Science, Vol. 14-2, pp. 1297 (1965), showed Blood does not clot when placed in graphite-coated tubes containing a cationic surface-active agent Agent and heparin treated and smiled with salt water
Aufgabe der Erfindung ist ein Verfahren zur dauerhaften,stair The object of the invention is a method for permanent, stair
bilen Bindung von Heparin an Polyethylenterephthalat.Bile binding of heparin to polyethylene terephthalate.
Die Aufgabe wird nach dem Verfahren der Erfindunr dadurch gelöst, dass das Polyethylenterephthalat mit einer ITatriumheparin und ein kationisches oberflächenaktives Mittel enthaltenden wässerigen Dispersion imprägniert, getrocknet und einer trockenen Hitze ausgesetzt wird, bis das Aieparin gleichmässig in die ^aserstruktur eingedrungen iso.The object is achieved according to the method of the invention in that the polyethylene terephthalate is impregnated with an aqueous dispersion containing sodium heparin and a cationic surface-active agent, dried and exposed to dry heat until the ai eparin has penetrated evenly into the aserstructure.
ψ Besonders günstig is ο uic Anwendung zi^ Herstellung nichttrombogener proathenischer Gegenstände, z. B. künstlicher Blutgefässe und dergleichen. ψ Particularly favorable is ο uic application for the production of non-thrombogenic proathenic objects, e.g. B. artificial blood vessels and the like.
Heparin ist zunächst hydrophil mit negativ geladenen Gruppen an der Oberfläche. Um in. die Faserstruktur bzw. das G-ewebe von Polyethylenterephthalat einzudringen, muss das ITatrium-Heparin is initially hydrophilic with negatively charged groups on the surface. To in. The fiber structure or the G-ewebe penetration of polyethylene terephthalate, the sodium
109841/1833109841/1833
211U67211U67
hen ar in mit; einem oberflächenaktiven Mittel eine Komplex-Bildung eingehen, dessen ladungsaktiver Teil an das Heparin gebunden wird, während die hydrophobe Gruppe nach aussen imd den Heparinkomplex hydrophob machtehen ar in with; complex formation with a surfactant enter, whose charge-active part is bound to the heparin, while the hydrophobic group to the outside imd made the heparin complex hydrophobic
In oberflächenaktiven Mitteln bildet die hydrophobe Grupne bei Lösung; in Wasser Teil eines Kations. Besonders günstig sind die Amine und die quaternären Ammoniumsalze. Geeignete primäre, sekundäre oder tertiäre Amine mit genügend grossen hydrophoben Gruppen sind z. B. die geradkettigen Fettamine mit 8-18 Kohlenstoffatomen. Typische Amine und quaternäre Ammoniumsalze sind z. B. Octadecylamin, N-(l-Methylheptyl)-Äthanolamin, Ii, N1-bis(Ί-Hethylheptyl)-Ethylendiamin, Trimethyloctadecylammoniumbromid und Kokusnussfett-Alkyldimethylbenzyl-Ammoniumchlorid. Kat-ionische, oberflächenaktive Stickstoffverbindungen sind aus stickstoffhaltigen Basen darstellbar, wie ζ. Έ. den Guanidinen, Hydrazinen, Aminoxiden und heterozyklischen, basischen Stickstoffverbindungen. Als Beispiel seien Laurylpyridinchlorid und Hexadecylpyridinbromid genannt. Weitere kationische, oberflächenaktive Mittel sind aus Sulfonium- oder Phosphoniumverbindungen darstellbar. In surfactants, the hydrophobic group forms upon solution; part of a cation in water. The amines and the quaternary ammonium salts are particularly favorable. Suitable primary, secondary or tertiary amines with sufficiently large hydrophobic groups are, for. B. the straight-chain fatty amines with 8-18 carbon atoms. Typical amines and quaternary ammonium salts are e.g. B. octadecylamine, N- (l-methylheptyl) -ethanolamine, Ii, N 1 -bis (Ί-ethylheptyl) -ethylenediamine, trimethyloctadecylammonium bromide and coconut oil-alkyldimethylbenzyl-ammonium chloride. Cat-ionic, surface-active nitrogen compounds can be prepared from nitrogen-containing bases, such as ζ. Έ. the guanidines, hydrazines, amine oxides and heterocyclic, basic nitrogen compounds. Examples are lauryl pyridine chloride and hexadecyl pyridine bromide. Further cationic, surface-active agents can be prepared from sulfonium or phosphonium compounds.
1098Λ1/18?31098-1 / 18? 3
_4-_ 211U67_ 4 -_ 211U67
Das Polyäthylenterephthalatgewebe wird von Öl- und Schmutz-. resten gereinigt und dann gleichmässig imprägniert, zo B. durch Eintauchen in eine wässerige Lösung von Heparin und oberflächenaktivem Mittel (meist z. B. 1 - 2 g NatriumheOarin auf 100 ecm HpO), oder in anderer geeigneter Weise.The polyethylene terephthalate fabric is covered by oil and dirt. purified residues and then uniformly impregnated, o for example, by immersion in an aqueous solution of heparin and surfactant (usually, for example, 1 -. 2 g NatriumheOarin to 100 cc HPO), or in another suitable manner.
Die sorgfältige Trocknung des gleichmässig imprägnierten Gewebes ist für das Verfahren besonders kritisch und erfolgt h am besten in zwei Stufen. Zunächst wird das Gewebe mit einem Infrarotstrahler vorgetrocknet, bis etwa 25 - 4-0?o des Wassergehalts ohne Wanderung des Heparinkomplexes entfernt sind. Sodann wird mit einem heissen Luftstrom die restliche Feuchte abgezogen. ·Careful drying of the evenly impregnated fabric is particularly critical to the process and takes place h best in two stages. First, the tissue is pre-dried with an infrared heater until about 25-4-0? O of the water content has been removed without the heparin complex migrating. The remaining moisture is then drawn off with a stream of hot air. ·
Anschliessend wird das Gewebe einer trockenen Wärmebehandlung, etwa bei 180 - 250° während 5 Sek. bis 10 Min., typischerweise 30 - 120 Sek., unterworfen. Auch hierfür ist z. B. ein Infrarotstrahler geeignet. Das fertige Produkt ist mit einerThe fabric is then subjected to a dry heat treatment, for example at 180-250 ° for 5 seconds to 10 minutes, typically 30 - 120 seconds, subject. Also for this is z. B. a Suitable for infrared emitters. The finished product comes with a
starken und gleichmässigen Heparinschicht überzogen, die das Gewebe gut durchdringt und sehr dauerhaft ist.thick and even layer of heparin, which penetrates the tissue well and is very durable.
Es wurde eine wässerige Lösung bereitet, die 0,3 g Natriumheparin-S*' , 0,04 g Hexadecylpyridinbromid, 2 ml einer ge-An aqueous solution was prepared containing 0.3 g of sodium heparin-S * ' , 0.04 g of hexadecylpyridine bromide, 2 ml of a
109841 /1833109841/1833
sättigten Lösung einer löslichen Stärke und 20 ml destilliertes Wasser enthielt. In diese Lösung wurde ein 1,5 x 1*5 cm grosses Polyäthylenterephthalatstück eingetaucht. Das imprägnierte Stück wurde getrocknet, 2 Min. unter einen 215° heissen Infrarotstrahler gelegt und dann 30 Min. in fliessendem Wasser gewaschen und getrocknet.saturated solution of a soluble starch and 20 ml of distilled water. A 1.5 x 1 * 5 cm large piece of polyethylene terephthalate dipped. The impregnated piece was dried, 2 min. Under a 215 ° hot infrared heater and then 30 min. in flowing Water washed and dried.
Die gebundene Heparinmenge wurde mit einem Beta-empfindlichen Proportionaldurchflusszähler gemessen und die Ausbeute durch · Pipettieren einer bekannten Menge von dispergiertem Heparin- S^ auf eine Messplatte bestimmt. Das behandelte Material wurde dann in 1000 ml kräftig gerührte 0,1 m NaOl-Lösung gegeben und von Zeit zu Zeit zur Bestimmung der Stabilität Proben entnommen. Die in der Zeichnung erläuterten Ergebnisse zeigen gute Stabilität der Heparin-S*-7 Aktivität des behandelten Materials in 0,1 m NaOl-Lösung, pH 5»8 bei 25° während 32 Stunden. Danach wurde der pH-Wert auf 8 erhöht und die Heparinaktivität während weiteren 68 Stunden gemessen. Das Oberflächenheparin ist besser als nach dem Gott Verfahren (s. o.) mit seinem Höchstwert von 2 Mikrogramm/cm .The bound Heparin amount was measured with a beta-sensitive proportional flow counter and the yield determined by · pipetting a known amount of heparin dispersed ^ S to a measuring plate. The treated material was then placed in 1000 ml of vigorously stirred 0.1 M NaOL solution and samples were taken from time to time to determine the stability. The results explained in the drawing show good stability of the heparin S * - 7 activity of the treated material in 0.1 M NaOL solution, pH 5 »8 at 25 ° for 32 hours. The pH was then increased to 8 and the heparin activity was measured for a further 68 hours. The surface heparin is better than after the God method (see above) with its maximum value of 2 micrograms / cm.
Polyäthylenterephthalatprosthesen wurden gemäss Beispiel I mit Heparin gebunden. Die Abschnitte wurden mit ÄthylenoxidPolyethylene terephthalate prostheses were made according to Example I. bound with heparin. The sections were made with ethylene oxide
109841/1833109841/1833
-β- 211U67-β- 211U67
sterilisiert, entgast und in die untere vena cava von IO Hunden eingesetzt. Die eingepflanzten Abschnitte zeipten raschen Blutdurchlauf ohne Anzeichen von Blutperinseln beim Einsetzen oder während der Operation nach öffnen des Blut-'durchlaufs. Nur durch Anlegen einer Packung um die Aussenflächen der Einpflanzstücke konnte eine Gerinselbildung undsterilized, degassed and placed in the lower vena cava of IO Dogs used. The planted sections zipped rapid blood flow with no signs of blood perisles upon insertion or during the operation after opening the blood flow. Just by putting a pack around the outer surfaces the planting pieces could form a clot and
. Hämastase hervorgerufen werden.. Haemastasis.
Der in einen der Hunde eingepflanzte Abschnitt blieb 9 Monate offen. In den übrigen Fällen trat nach 1-4 Wochen eine Trombose ein. Die Autopsie zeigte jedoch, dass die Innenflächen.der Einpflanzabschnitte praktisch frei von Tromben waren und die Trombose an oder nahe den Anastomosen der Gastgefässe begann. Durch Bindung an Heparin wurde also eine Blutgerinnung längere Zeit ausgeschlossen.The section planted in one of the dogs remained open for 9 months. In the remaining cases one occurred after 1-4 weeks Thrombosis a. However, the autopsy showed that the inner surfaces of the Implant sections were practically free of thrombi and the thrombosis was at or near the anastomoses of the guest vessels started. By binding to heparin, blood coagulation was excluded for a long time.
109841/1833109841/1833
Claims (5)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2112670A | 1970-03-19 | 1970-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2111467A1 true DE2111467A1 (en) | 1971-10-07 |
Family
ID=21802477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712111467 Pending DE2111467A1 (en) | 1970-03-19 | 1971-03-10 | Method for binding heparin to polyethylene terephthalate |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE764487A (en) |
| CA (1) | CA960583A (en) |
| DE (1) | DE2111467A1 (en) |
| FR (1) | FR2084813A5 (en) |
| GB (1) | GB1294788A (en) |
| NL (1) | NL7103642A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE425372B (en) * | 1977-07-18 | 1982-09-27 | Ird Biomaterial Ab | SET TO HEPARINIZE AN ELECTRICALLY CHARGED SURFACE ON A MEDICAL ARTICLE INTENDED TO CONTACT WITH BLOOD AND MEDICINES TO PERFORM THE SET |
-
1971
- 1971-03-10 DE DE19712111467 patent/DE2111467A1/en active Pending
- 1971-03-10 CA CA107,354A patent/CA960583A/en not_active Expired
- 1971-03-18 FR FR7109511A patent/FR2084813A5/fr not_active Expired
- 1971-03-18 BE BE764487A patent/BE764487A/en unknown
- 1971-03-18 NL NL7103642A patent/NL7103642A/xx unknown
- 1971-04-19 GB GB2349371A patent/GB1294788A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE764487A (en) | 1971-09-20 |
| FR2084813A5 (en) | 1971-12-17 |
| GB1294788A (en) | 1972-11-01 |
| CA960583A (en) | 1975-01-07 |
| NL7103642A (en) | 1971-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69019512T2 (en) | PREVENTING CALCIFICATION IN BIOPROSTHETIC IMPLANTS. | |
| DE3608158C2 (en) | ||
| DE69534671T2 (en) | CALCULATION RESISTANT BIOPROTHETIC TISSUE AND MANUFACTURING METHOD | |
| DE2831360A1 (en) | METHOD AND MEANS FOR HEPARINIZING A CHARGED SURFACE OF A MEDICAL OBJECT | |
| DE2025714C3 (en) | Process for producing heparin-containing surfaces with an anticoagulant effect on blood on objects made of plastic, glass and metals | |
| DE3504724A1 (en) | METHOD FOR ENCLOSURE A MATERIAL TO BE ENCLOSED | |
| EP0010621A1 (en) | Method of fabricating a permanent catheter of plastics material with a negatively charged surface, and catheter produced by this method | |
| DE3503127A1 (en) | COLLAGEN-COVERED SYNTHETIC VESSEL REPLACEMENT | |
| DE1642018B1 (en) | Surgical sutures | |
| DE1806115A1 (en) | Method for preventing blood coagulation on surfaces of artificial objects | |
| DE910950C (en) | Process for the production of artificial structures by shaping solutions of casein or similar protein substances | |
| DE2111467A1 (en) | Method for binding heparin to polyethylene terephthalate | |
| DE2601289C3 (en) | Method for sealing synthetic velor vascular prostheses | |
| CH370235A (en) | Process for the production of artificial sponges from regenerated cellulose and sponge produced in this way | |
| EP0606866A1 (en) | Process for inhibiting the breaking of bamboo canes (chemical) | |
| DE2154542A1 (en) | Antithrombogenic plastic body | |
| DE659116C (en) | Process for finishing wool fibers | |
| DE1944596A1 (en) | Process for dyeing keratinous fibers | |
| DE551316C (en) | Process for the protection of textile materials in particular against attack by powdery mildew or other fungus-like plants | |
| DE2914018A1 (en) | METHOD FOR PRODUCING BIOCompatible MATERIALS OF THE POLYAMIDE TYPE AND ITEMS OBTAINED THEREFORE | |
| EP0069156B1 (en) | Method for the preparation of transplants with higher biological stability | |
| DE1200662B (en) | Process for the treatment of mature cheese according to Swiss style | |
| DE2118464C3 (en) | ||
| DE377487C (en) | Process for the manufacture of leather from daermen | |
| DE877379C (en) | Moth repellent |